VEGFA and diffuse large B-cell lymphoma: In our study, the results of Figure 1 and Figure 2 displayed that after therapy, levels of VEGF, TKI and IL-6 levels, as well as plasma T cells, NK cells together with B cells in the RG presented lower relative to the CG, indicating that rituximab combined with chemotherapy could better reduce the inflammatory response and promote the immune function of DLBCL patients.